Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential afatinib plus short-course chemotherapy followed by osimertinib plus short-course chemotherapy in untreated EGFR-mutant NSCLC
NL-OMON52389Phase 2Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Feb 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib, osimertinib, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Vrije University Medical Center. Primary endpoints: Disease control rate at 18 months, Safety and 2 more. Started Feb 2021; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52389.